Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Third-Party Vendor Qualification (Labs, Courier) – V 2.0

Posted on By

BA-BE Studies: SOP for Third-Party Vendor Qualification (Labs, Courier) – V 2.0

Standard Operating Procedure for Third-Party Vendor Qualification (Labs, Courier) in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/039/2025
Supersedes SOP/BA-BE/039/2022
Page No. Page 1 of 13
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the standardized process for evaluating, qualifying, and approving third-party vendors including bioanalytical labs, logistics providers, and courier services involved in Bioavailability/Bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all external vendors providing critical services in BA/BE studies sponsored or managed by the organization. This includes bioanalytical laboratories, central labs, sample transport couriers, and document logistics partners.

3. Responsibilities

  • Quality Assurance (QA): Leads vendor audit and qualification process.
  • Clinical Project Manager: Initiates vendor selection and coordinates documentation flow.
  • Regulatory Affairs: Confirms licensing and accreditation status of vendor.
  • Procurement: Ensures agreements, pricing, and contracts are in place post-qualification.
See also  BA-BE Studies: SOP for Pre-Submission Meeting with Regulatory Authorities - V 2.0

4. Accountability

The Head of Quality is accountable for ensuring that no unqualified or unapproved vendor is engaged in any critical trial-related activity that can impact subject safety or data integrity.

5. Procedure

5.1 Vendor Identification and Initiation

  1. Identify potential vendors based on study requirements and geographical feasibility.
  2. Send Annexure-1: Vendor Prequalification Questionnaire for initial screening.

5.2 Documentation Review

  1. Collect the following from the vendor:
    • Company profile and GMP/GLP certification
    • List of equipment and validation records
    • Sample transportation SOPs and temperature monitoring procedures
    • Quality policy and past audit reports (if applicable)

5.3 Site Audit and Technical Evaluation

  1. Conduct an on-site or remote audit using Annexure-2: Vendor Audit Checklist.
  2. Evaluate parameters including:
    • Sample handling capacity and storage conditions
    • Turnaround time and contingency plans
    • Personnel training and documentation practices
See also  BA-BE Studies: SOP for Ethics Committee Submission Requirements - V 2.0

5.4 Approval and Onboarding

  1. Document findings in Annexure-3: Vendor Qualification Summary.
  2. Obtain final approval from QA Head using Annexure-4: Vendor Approval Form.
  3. Enter qualified vendor into Annexure-5: Approved Vendor Master List.

5.5 Periodic Requalification

  1. Vendors shall be re-evaluated every 2 years or after significant non-compliance events.
  2. Conduct spot audits if required and update qualification status accordingly.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • GLP: Good Laboratory Practice
  • QA: Quality Assurance
  • SOP: Standard Operating Procedure

7. Documents

  1. Vendor Prequalification Questionnaire – Annexure-1
  2. Vendor Audit Checklist – Annexure-2
  3. Vendor Qualification Summary – Annexure-3
  4. Vendor Approval Form – Annexure-4
  5. Approved Vendor Master List – Annexure-5

8. References

  • ICH E6(R2) – Good Clinical Practice
  • OECD Principles of GLP
  • WHO Guidelines for the Preparation of BA/BE Protocols

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department
See also  BA-BE Studies: SOP for Translation and Back-Translation of Consent Forms - V 2.0

11. Annexures

Annexure-1: Vendor Prequalification Questionnaire

Item Response
GLP Certified? Yes – NABL Accreditation Valid Till 2026
Cold Chain Experience? Yes, 2–8°C with data loggers

Annexure-2: Vendor Audit Checklist

Audit Area Criteria Compliant (Y/N) Remarks
Sample Handling Chain of custody documented Y Well maintained logs

Annexure-3: Vendor Qualification Summary

Vendor Name Service Audit Date Qualified By Status
Biotrack Labs Pvt. Ltd. Bioanalysis 12/04/2025 Sunita Reddy Qualified

Annexure-4: Vendor Approval Form

Vendor Approved By Date Signature
TrackFast Couriers Dr. Arvind Shah 17/04/2025

Annexure-5: Approved Vendor Master List

Vendor Name Service Type Valid From Valid To Status
ColdXpress Logistics Sample Courier 01/01/2024 31/12/2025 Active

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP New vendor qualification process QA Head
17/04/2025 2.0 Added courier evaluation, updated annexures Audit and regulatory alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Capsule: SOP for Documenting QC Test Results for Capsules – V 2.0
Next Post: Aerosol: SOP for Photostability Testing of Aerosol Formulations – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version